Zubi Capital
VC Fund
Valencia, Spain
Zubi Capital is a dedicated and independent Asset Management and Wealth Management firm.We create innovative impact investment and advisory solutions that incorporate current and future environmental and social opportunities and risks, as we believe these will benefit from a competitive advantage and improved long-term financial prospects.Weview impact investing as an integral part of any asset class and a core part of an enlightened investor’s overall portfolio.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 42%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Zubi Capital invests in
Stages Zubi Capital invests in
Countries Zubi Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.1M–$8.7M
- Series A
- $16M–$16M
- Debt Financing
- $328k–$6.5M
Investment Focus
Industry
- Health Care 4 (17%)
- FinTech 3 (13%)
- Biotechnology 3 (13%)
- Finance 2 (8%)
- Software 2 (8%)
Stage
- Seed 11 (46%)
- Debt Financing 4 (17%)
- Series A 2 (8%)
- Venture - Series Unknown 2 (8%)
- Pre-Seed 1 (4%)
Country
- Spain 10 (42%)
- United States 2 (8%)
- France 1 (4%)
- Finland 1 (4%)
- Germany 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jaivir Pall
Investment Director
|
Investment Director | Total investments: 1 | Find email | |
José Nistal
CEO
|
CEO | Total investments: 0 | Find email | |
|
Marc Guasch
Investment Director
|
Investment Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HUMARA is a software platform that supports the design and management of waste treatment and recycling plants, helping users plan facility layouts, simulate processes, and organize equipment and operations for waste management projects. | $1.4M / Seed / May 06, 2026 | ||
| A biotech platform to scale applied material science. | $16.3M / Series A / Jan 19, 2026 | ||
| Abvance Therapeutics is a biotechnology research company that focuses on innovative solutions to address unmet needs in diabetes care. The company is known for developing a novel coformulation of insulin and glucagon, which could revolutionize diabetes care. This treatment combines two well-understood and FDA-approved peptides to control glycemiawhile mitigating the threat of hypoglycemia. The company's team of scientists and physicians have discovered this unique approach to diabetes treatment, aiming to reduce hypoglycemia and improve patient outcomes. | Seed / Jun 24, 2025 | ||
| Matteco is a materials technology company | $16.2M / Series A / Oct 23, 2024 | ||
| Ancilia Biosciences develops engineered bacterial therapies to treat diseases linked to the microbiome. It provides and develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. | $4.2M / Venture - Series Unknown / Jul 17, 2024 | ||
| Tecfys provides technology services that includes home appliances and electronic equipment by paying monthly subscriptions.They promote the circular economy through circular subscription. They offer a guarantee throughout the subscription period. They offer products for you to use on a subscription basis. | $6.5M / Debt Financing / May 13, 2024 | ||
| We unlock energy insights to everyone through energy retailers | $1.6M / Seed / Jan 31, 2024 | ||
| MYHIXEL is a scientific and medical backed solution for male sexual well-being. | $328K / Debt Financing / Jan 09, 2024 | ||
| Kausal is a digital platform that facilitates smarter collaboration around essential data to assist cities in setting their climate goals. Kausal Watch web publishing platform collects all the data on the actions that your city is taking for climate mitigation. | $930.9K / Seed / Oct 31, 2023 | ||
|
Tupu
|
Tupu engages in the manufacture and supply of mushroom-based foods. | $3.2M / Seed / Oct 31, 2023 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Zubi Capital invest in?
Zubi Capital invests primarily in Health Care, FinTech and Biotechnology startups, most often at Seed and Debt Financing stage. Most of the 24 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Zubi Capital invest in?
Zubi Capital typically joins rounds of $1.1M–$8.7M at Seed, $16M–$16M at Series A and $328k–$6.5M at Debt Financing. These are whole funding-round sizes, not Zubi Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Zubi Capital took part in.
How do I contact Zubi Capital?
Public channels for Zubi Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Zubi Capital?
The team at Zubi Capital includes Jaivir Pall (Investment Director), José Nistal (CEO) and Marc Guasch (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
